CGeneTech was selected as a finalist in the 7th China Innovation and Entrepreneurship Competition for Biomedical Industry

Categories:Company News
Author:admin
Origin:
Time of issue:2018-11-14
Views:0

(Summary description)The 7th China Innovation and Entrepreneurship Competition Biopharmaceutical Industry Finals was held in Guangzhou from November 12-15, 2018. The event is the ultimate competition of biomedical innovation power in the national finals, and will also build a state-level platform for the integration and development of resources from all sides in Guangzhou. Biomedicine is known as the "crown jewel" of the new round of technological revolution. In the national "treasure" on the road, hundreds of billions of emerging industries are rising, leading to the vigorous development of the health industry. Nowadays, there are many innovative ventures in the biomedical industry, and a large number of new biomedical stars have emerged from the competition.

CGeneTech was selected as a finalist in the 7th China Innovation and Entrepreneurship Competition for Biomedical Industry

(Summary description)The 7th China Innovation and Entrepreneurship Competition Biopharmaceutical Industry Finals was held in Guangzhou from November 12-15, 2018. The event is the ultimate competition of biomedical innovation power in the national finals, and will also build a state-level platform for the integration and development of resources from all sides in Guangzhou. Biomedicine is known as the "crown jewel" of the new round of technological revolution. In the national "treasure" on the road, hundreds of billions of emerging industries are rising, leading to the vigorous development of the health industry. Nowadays, there are many innovative ventures in the biomedical industry, and a large number of new biomedical stars have emerged from the competition.

Categories:Company News
Author:admin
Origin:
Time of issue:2018-11-14
Views:0

The 7th China Innovation and Entrepreneurship Competition Biopharmaceutical Industry Finals was held in Guangzhou from November 12-15, 2018. The event is the ultimate competition of biomedical innovation power in the national finals, and will also build a state-level platform for the integration and development of resources from all sides in Guangzhou. Biomedicine is known as the "crown jewel" of the new round of technological revolution. In the national "treasure" on the road, hundreds of billions of emerging industries are rising, leading to the vigorous development of the health industry. Nowadays, there are many innovative ventures in the biomedical industry, and a large number of new biomedical stars have emerged from the competition.

The strength of biomedical finalists in this year's national finals is not to be underestimated. There are 3667 biomedical companies among more than 30,000 participating companies nationwide, and they have been selected through local preliminary, final and final rounds, and finally 235 outstanding companies have advanced to Guangzhou, among which, the number of finalists from Yunnan, Shanghai, Guangdong and Jiangsu are the most. From the perspective of the projects, innovative devices, precision medicine, genetic testing, new drug research and development, regenerative medicine, medical equipment, in vitro diagnostics, Internet + medical technology and other fields will be on the same stage to show technology.

Participating companies will compete in the "semi-finals + finals" promotion pathway, the semi-finals and finals will be held on November 14 and 15, respectively. The semi-finals will be promoted by group competition, and all finalists will be divided into 3 start-up groups and 7 growth groups for group roadshow. 8 minutes of project roadshow and 7 minutes of Q&A interaction will constitute the whole competition. The semi-finals will evaluate 101 outstanding companies, and at the same time determine the top 6 start-ups and top 14 growing companies in the country, leading to the final competition for the crown. The first, second and third prizes in the national biomedical field will be awarded at the final round.
*** Translated with www.DeepL.com/Translator (free version) ***

Team CGeneTech, represented by Pan Huiping, excelled in the finals and won the National Excellence Award in the 2018 Innovation and Entrepreneurship Competition. Coinciding with today's United Nations Diabetes Day, we have been on our way as an innovative company leading the way with the development of hypoglycemic drugs.

In fact, the predecessor of the United Nations Diabetes Day (World Diabetes Day' WDD) was co-sponsored by the World Health Organization and the International Diabetes Federation in 1991, with the aim of causing global awareness and awakening to diabetes.

At the end of 2006, the United Nations adopted a resolution to change the name of World Diabetes Day to United Nations Diabetes Day from 2007 onwards, elevating expert and academic actions to governmental actions in all countries, and urging governments and all sectors of society to strengthen the control of diabetes and reduce the risk of diabetes. The United Nations adopted a resolution at the end of 2007 to formally rename World Diabetes Day as "United Nations Diabetes Day", which elevates expert and academic actions to the actions of national governments, prompting governments and all sectors of society to strengthen the control of diabetes and reduce its harmful effects.

目前，盛世泰科已与包括江苏省人民医院在内的机构达成协议，开展磷酸盛格列汀的Ⅰ期临床试验。磷酸盛格列汀属于二肽基肽酶(DPP)-4抑制剂类药物，此类药物最大的优势是不会引起低血糖和体重增加，且具有心血管保护作用；同时，由于中国2型糖尿病患者的胰岛β细胞受损程度比欧美患者更严重，而DPP-4抑制剂类药物的特点之一是可以改善β细胞受损，因而中国患者能更多地获益，这使得DPP-4抑制剂类药物在中国越来越受到医生的认可。

磷酸盛格列汀是国家“十二五”和“十三五”重大新药创制专项和江苏省“科技支撑计划”专项，是完全自主研发的糖尿病新药。磷酸盛格列汀的临床前研究显示，其有效性是全球最优药物磷酸西格列汀（捷诺维）的3-10倍，安全性是磷酸西格列汀的5倍以上，优势十分明显。磷酸盛格列汀的成功上市，将为数亿中国2型糖尿病患者带来一种更加实惠和安全有效的药物选择，并将进一步提高我国2型糖尿病的治疗水平。盛世泰科将始终以自主创新作为企业发展的源动力，继续承担中国重大疾病新药研发的使命，与国内外学术力量紧密合作，积极开拓中国医药科技产业化的发展之路，造福中国广大患者。

Previous: CGeneTech Receives Project Support from the "13th Five-Year Plan National Major New Drug Creation Project

Next: Formulation innovation sharing, chemistry frontiers at PharmaCon2018

Previous: CGeneTech Receives Project Support from the "13th Five-Year Plan National Major New Drug Creation Project

Next: Formulation innovation sharing, chemistry frontiers at PharmaCon2018

CGeneTech: Exchange 'One Promise, One Thousand Gold' for 'Dreams Come True'

Introduction: Adhere to our original aspiration, forge ahead, and let our dreams shine into reality. The rapid development of Suzhou Industrial Park is the result of generations of park residents' continuous efforts, and also embodies the strength of each enterprise's rooting and growth. Enterprises are witnesses, but also participants. In the park, one group after another of enterprises have run the "upward trend" with their own "hard skills", using abundant vitality as ink and strong resilience as pen, writing a wonderful chapter of "striving for thirty years and building dreams towards the future". On the occasion of 15 years of rooting in Suzhou Industrial Park, Shengshi Taike Biopharmaceutical Technology (Suzhou) Co., Ltd. has reached a major development milestone - the company's first independently developed Class 1 innovative drug, sitagliptin phosphate tablets, has been approved for listing in China. The founder and CEO of Shengshi Taike, Yu Qiang, wrote a poem with deep emotion: "The trees and trees are all singing in heaven, and the colors are shining in the hall. The morning sun shines on the clouds, and the prosperous era welcomes the sunrise The original intention of entrepreneurship and the passion for innovation are intertwined at this moment into a beautiful story of the "two-way rush" between the park and talents. The successful approval of sengliptin for listing is due to the entrepreneurial fertile ground of Suzhou and the park, as well as the strong support of many departments. It is also a way to repay the park's pro business services with our innovative drugs, "said Yu Qiang. Since settling in the park in 2010, Shengshi Taike has been based in Suzhou and has a global perspective, focusing on the research and production of small molecule innovative drugs. With an integrated drug research and development technology platform and diversified business vision, it has built a rich pipeline of innovative drugs covering areas such as blood sugar reduction, anti-cancer, and autoimmune。 Funds - the 'first pot of gold' that leverages innovation leverage In 2010, with rich scientific research and practical experience in the field of pharmaceutical research and development, Yu Qiang and partner Ding Juping established Shengshi Taike in Suzhou Biomedical Industry Park (BioBAY), committed to the research and industrialization of breakthrough small molecule innovative drugs for therapeutic purposes. "China is a big country with diabetes in the world, and the number of patients with diabetes is the first in the world. In 2008, I heard the news that China began to attach importance to the biomedical industry. Around 2010, I decided to bring my initial research and development achievements, raise funds, form a team, and return to China to make a new class of hypoglycemic drugs." Recalling more than a decade ago, Yu Qiang still remembers. The decision to return to China and start a business in the park was impressed by the numerous emails exchanged. At that time, I was still in the United States and consulted the park government about entrepreneurship issues through email. The response I received was not only fluent in English, but also highly professional. The fact has proven that my initial choice was the right one The beginning of everything is difficult. Even if the conditions for starting a business in China are relatively mature, for a new drug research and development company in the start-up stage, the challenges it faces can be imagined. Shortage of funds is the first problem. Fortunately, the park provides very strong financial support to leading talents, "said Yu Qiang. When he settled in 2010, the park could offer a" big gift package "of up to 10 million yuan to leading talents in the biopharmaceutical field, including housing subsidies, rent reductions, subsidized loans, start-up capital, etc. More importantly, the predecessor of Yuanhe Holdings, Zhongxin Venture Capital, gave us 6.5 million yuan in angel investment, which can be said to be a" timely help "for start-up companies. Later, the company's new drugs were successively shortlisted for the national "Twelfth Five Year Plan", "Thirteenth Five Year Plan" and "Major New Drug Creation" special projects, and were included in the national key support track, further obtaining financial support. The guidance fund and leading venture capital of the park's enterprise development service center have provided financing support at different stages of Shengshi Taike's development. With the guidance of government industry funds, they have also attracted more social capital to invest and jointly support enterprise innovation. I have always believed that it is the '1' given by the park that leads to the '0' increase in social capital in the future, "Yu Qiang said with a smile. Funds support the growth of enterprises and drive industrial development. At present, Shengshi Taike has built a rich drug pipeline, with product distribution fr

2025-01-07

Milestones | Shengshi Taike's new generation DPP-4 inhibitor approved for market launch

Today, the official website of the National Medical Products Administration (NMPA) of China announced that Shengshi Taike's independently developed Class 1 innovative drug, saxagliptin phosphate tablets (formerly known as saxagliptin phosphate tablets), has been approved for market in China. This is a new generation of highly selective DPP-4 inhibitor, which is suitable for improving the blood sugar control of adult type 2 diabetes patients. According to the Guidelines for the Prevention and Treatment of Type 2 diabetes in China, the prevalence of diabetes among adults in China has risen to 11.2%, of which more than 90% are type 2 diabetes. In order to meet the huge clinical demand, some new drugs with different mechanisms of action from traditional oral hypoglycemic drugs have emerged in recent years. Dipeptidyl peptidase-4 (DPP-4) inhibitors are one of them. They not only improve hyperglycemia, but also are not easy to induce hypoglycemia and weight gain. They have the characteristics of rapid oral absorption, long half-life, and long-lasting effect, and are known as "smart" hypoglycemic drugs. Currently, they have been recommended by many domestic and foreign guidelines. As a new generation of highly selective DPP-4 inhibitor independently developed by Shengshi Taike, sengliptin has been continuously selected for the national "Major New Drug Development" special projects in the 12th and 13th Five Year Plans. Due to the excellent data demonstrated in the first phase clinical trial of the best product in the market, it was exempted from phase 2 clinical trials and directly entered phase 3 clinical trials, pioneering the "exemption from two to three" clinical trials in the field of this drug. The results of the phase III clinical trial of Sengliptin led by Professor Ji Linong, director of the Endocrinology Department of Peking University People's Hospital and director of Peking University diabetes Center, showed that in the single drug treatment trial of Sengliptin, the reduction values of HbA1c in the 50mg and 100mg dose groups at the end of the 24th week were 1.08% and 1.07% respectively; In the treatment trial of sengliptin combined with metformin, the glycated hemoglobin decreased by 1.23% and 1.17% in the 50mg and 100mg dose groups at the end of the 24th week, respectively. Meanwhile, both sets of experimental data showed that patients with higher blood sugar levels experienced a greater decrease in glycated hemoglobin levels. In addition to its excellent hypoglycemic effect, what is even more commendable is that in the comparison between the 100mg dose group (high-dose group) and the placebo group in the last 28 weeks, the incidence of adverse reactions of sengliptin is similar to that of the placebo group, and its safety further solves the common adverse reactions in marketed products. At present, metformin combined with leptin has become the main treatment scheme in the clinical application of treating type 2 diabetes. According to Sullivan's research report, by 2030, the market size of leptin in China will exceed 30 billion, with broad market prospects. Ding Juping, the co-founder and president of Shengshi Tyco, said: "I am very glad to see the company's self-developed product, Sengliptin Phosphate Tablets, has been approved for listing. This drug will be the best new hypoglycemic drug of its kind with half the effort and twice the treatment effect. I hope it will benefit the majority of diabetes patients in China as soon as possible after it is approved for listing." Dr. Yu Qiang, the founder and CEO of Shengshi Tyco, said: "Sengliptin's successful approval for listing benefits from Suzhou and the park as a fertile land for entrepreneurship and the strong support of many departments. It is also a" promise of gold "to use our innovative drugs to repay the business friendly services in Suzhou Park. At this moment, I would like to use an original poem to bless this new drug for its successful launch." Morimu's sounds of nature are listed in the palace. The morning light shines on the clouds, and the prosperous world welcomes the sunrise.

2024-12-05